The aim of this review is to evaluate recent immunophenotype knowledge of hematopoietic stem cells and their restricted progenies committed to myeloid lineage -common myeloid progenitors, myelo-monocytic progenitors, megakaryo-erythroid progenitors and granulocyte progenitors up to mature neutrophil granulocyte. This study evaluates also recent knowledge of immunophenotype of leukemic stem cells and their more differentiated progeny committed to myeloid lineage -acute myeloid leukemia blast cells with regard to their phenotypic similarity to normal stem and granulocyte committed progenitor cells. Improved knowledge of normal stem and progenitor cells phenotypes, identifying new leukemia-specific markers, searching for aberrant marker expression and evaluation of aberrant intensity or combination of various marker expressions is important for distinguishing normal cells from their malignant counterpart in view of the diagnostics of leukemias or follow-up of minimal residual disease.
Bone marrow is a mesenchyme-derived complex structure consisting of hematopoietic precursors, hematopoietic mature cells and stromal cells which provide a complex microenvironment that facilitates the maintenance of hematopoietic stem cells (HSCs) and supports the differentiation and maturation of the progenitors. In general, hematopoietic stem cells are defined as a clonogenic cells with self-renewing and multilineage differentiation capacity in vivo. HSCs give rise to nonself-renewing oligolineage-restricted progenitors which in turn give rise to progeny that is more restricted in its differentiation potential and finally to functionally mature cells [1, 2] .
Normal stem and progenitor cells. The normal hematopoietic process of HSCs differentiation and maturation is characterized by gradually increasing or decreasing expression of specific surface markers which allows recognition of various stages of cell differentiation and assessment of commitment to different lineages (e.g. lymphoid, myeloid and erythroid) [3, 4] . Flow cytometry method enables studying hematopoiesis according to the cell-surface expression of specific CD molecules and their expression patterns are used to characterize the differentiation stages of cells belonging to various hematopoietic lineages. The development of multiparameter fluorescence-activated cell sorting (FACS) has enabled purification and high enrichment of HSCs and their progeny cells. HSCs and their more mature progeny cells reside within CD34 + cell fraction and comprise ~ 0,2-3% of the nucleated cells in bone marrow, cord blood and mobilized peripheral blood [5, 6, 7] . Therefore, CD34 + cell population is heterogeneous. Only a small fraction (1-10%) of CD34 + cells does not express CD38 and lineage specific markers (Lin) [8] and contains cells with lymphoid and myeloid differentiation potential [9, 10, 11, 12] . The majority of CD34 + cells (90-99%) coexpress CD38 antigen and this subset represents most of the lineage-restricted progenitors [13] .
Assays for the determination of progenitor cells maturation. Various forms of in vitro clonogenic assays (colony forming assay, long-term culture initiating cell assay, LTC-IC) were developed for the determination of maturation and differentiation of HSCs and their more mature hematopoietic progenitor cells. These assays are very useful to define a variety of progenitors and provide the proof of self-renewal capacity or multilineage differentiation potential [11, 12, 14, 15] . However, major functional properties of the HSCs i.e. bone marrow repopulating capacity and ability to maintain longterm hematopoiesis, cannot be studied in in vitro clonogenic assays. To analyze the functional properties of HSCs in vivo xenotransplant animal models were developed. The most suitable models are mice with non-obese diabetes and severe combined immunodeficiency (NOD/SCID mice). In such mice, human HSCs can repopulate the entire hematopoietic system (except T cells) [16] and can undergo unlimited selfrenewal [17, 18, 19, 20] . Limited life-span of NOD/SCID mice in particular and tendency towards human B-cell development also resulted in creation of alternative xenotransplantation models [13] . Srour et al. [21] and Zanjani et al. [22] established a large animal transplantation model in which human HSCs are transplanted intraperitoneally into unconditioned, early gestational sheep fetuses.
Hematopoietic stem cells
All normal hematopoietic cells are continually generated from a small pool of pluripotent HSCs residing in bone marrow. The first experimental evidence indicated HSCs discovery in 1961 by Till and McCulloch [23] who described a population of clonogenic bone marrow cells capable of generating myelo-erythroid colonies in the spleen of lethally irradiated hosts. HSCs can be divided into a long-term subset (LT-HSC), capable of self-renewal for the whole life of the host, and a short-term subset (ST-HSC) that retain self-renewal capacity for approximately 8 weeks [24] . LT-HSCs are able to maintain in NOD/SCID mice for prolonged period and their further retransplantation into secondary lethally irradiated host can reconstitute the immune system again [23] 
Lin
-HSCs were able to self-renew and differentiate in vitro in LTC-IC, contained NOD-SCID-repopulating cells [14, 17] and some of them were able to detect even in secondary NOD-SCID transplants [28, 20] . However, CD34 + CD38 -
-cell fraction are still very heterogeneous with regard to surface marker expression. Recent immunophenotype studies of HSCs have showed various (negative, low or medium) expression of additional progenitor CD markers CD90 (Thy-1), CD117 (c-Kit), CD123 (IL-3Rα), CD135 (Flt3), medium expression of CD45, HLA-DR, CD133 (Prominin); low forward scatter (FSC) and side scatter (SSC) characteristics [9, 29, 30, 25] .
Heterogeneous CD38 marker expression was observed by Ziegler et al. [28] 
CD33
-cell fraction. However, the data published by Taussig et al. [32] are in contrast to later in vitro results of Andrews et al. [33, 34] 
Lin
-cells in the hematopoietic hierarchy.
Types of lineage-restricted progenitors according to classical model of lymphohematopoetic differentiation
HSCs undergo cell division, become lineage-restricted and ultimately turn into unipotent progenitor cells. Differentiation of HSCs to mature cells of lymphohematopoietic system involves progressive loss of self-renewal capacity, proliferation ability and multilineage potential. Classical (dichotomy) model of the lymphohematopoietic differentiation have been elucidated mainly in studies of the murine hematopoiesis. According to this model LT-HSCs differentiate into ST-HSCs retained self-renewal capacity for ~ 8 weeks [9] and give rise to shortly self-renewing multipotent progenitors (MPPs) [39] , which then differentiate into a common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs). CLPs are restricted to give rise to T lymphocytes, B lymphocytes, and natural killer cells [40] . CMPs give rise to myelo-monocytic progenitors (GMPs), which in turn produce monocytes/ macrophages and granulocytes, and to megakaryo-erythroid progenitors (MEPs), which differentiate into megakaryocytes/ platelets and erythrocytes [41] . Interestingly, both CMPs and CLPs can give rise to dendritic cells [41, 42, 43] . All lineage-restricted progenitors reside within CD34 + CD38
low/+ cell fraction [17, 44] .
Phenotype of common lymphoid progenitors. Galy et al. [45] showed that fetal and adult bone marrow CD34 -produced mainly burst-forming units erythroid, CFU-megakaryocyte, CFU-megakaryocyte-erythroid. CMPs, GMPs, and MEPs cell populations displayed relatively uniform levels of CD117 (cKit), CD13, CD33, and HLA-DR and were negative for CD90 (Thy-1).
However, the separation of the CMPs and MEPs populations based on their moderately different CD123 (IL-3Ra) expression is difficult to achieve. Therefore, Edvardsson et al. [48] found a complementary MEP surface marker -thrombopoietin receptor (TpoR, CD110) and obtained a more effective separation of these two progenitor populations for their further characterization. -are enriched for erythroid-colony forming cells [13] .
Other models of lymphohematopoietic differentiation
Some recent studies have indicated discrepancies in classical model of the lymphohematopoietic differentiation. Mori et al. [49] published study of human eosinophil differentiation in vitro. They showed that HSCs and CMPs generate CFUgranulocyte-macrophage and CFU-megakaryocyte-erythroid, whereas GMPs and MEPs give rise mainly to neutrophils, monocyte/macrophage and megakaryocyte-erythroid cell colonies, but without developing into the eosinophil lineage. Therefore they proposed that the eosinophil progenitor (EoP) develops from the CMP or its upstream MPP independent of the GMP and the MEP. Mori et al. [49] Alternative, so-called 'myeloid-based model' of the lymphohematopoietic differentiation was proposed by Katsura and Kawamoto [50] . This model postulates that the HSC first diverges into the common myeloid-erythroid progenitor (CMEP) and a common myelo-lymphoid progenitor (CMLP). The CMLP then generates T and B cell progenitors through a bipotential myeloid-T progenitor and a myeloid-B progenitor stage, respectively. The major difference between the myeloid based model and the classical model is that the potential to generate myeloid cells is retained in all erythroid, T, and B lineage branches in the myeloid-based model [51] . This alternative model is supported by studies using mice that showed retaining of myeloid potential in the early lymphoid progenitors in adult murine bone marrow [52] .
Kawamoto et al. [53, 54, 55 ] also analyzed developmental potential of individual progenitors towards T, B, and myeloid lineages in the murine fetal liver by in vitro clonal assay. They showed consistent detection of progenitors generating myeloid and T cells and progenitors generating myeloid and B cells in the face of the complete absence of progenitors generating T and B cells without myeloid cells. Furthermore, the application of the myeloid-based model seems to explain origin of bi-phenotypic leukemia cases when myeloid-B and myeloid-T types are commonly seen, but the T-B type is rare [56, 57] .
Phenotype of granulocyte progenitors
Common myeloid progenitor gives rise to 7 various cell lineages -neutrophil granulocytes, basophil granulocytes, eosinophil granulocytes, monocytes/macrophages, erythrocytes, megakaryocytes/platelets and mastocytes. Differentiation of the neutrophil progenitors is better characterized because eosinophil and basophil progenitors comprise only minor subpopulations in normal BM.
Neutrophils mature from myelo-monoblasts through a linear process, historically divided into morphological stages termed promyelocytes, myelocytes, metamyelocyte band cells, and neutrophils. Promyelocytes are defined by acquisition of CD15 and CD66b; acquisition of CD11b, CD11c, CD24, and CD66a is characteristic for myelocytes; gain of CD55, CD16, CD35 and CD87 for metamyelocyte band cells and gain of CD10 for mature neutrophil granulocytes.
CD13 is a unique marker in the granulocytic differentiation as it is dynamically expressed during granulocytic differentiation. It is expressed at high levels on myeloblasts and promyelocytes. CD13 is downregulated and dimly expressed on myelocytes and is gradually upregulated again as the granulocytic cells develop into segmented neutrophils. Similarly, CD44 and CD55 are highly expressed in myelo-monoblast stage, then exhibit a decrease at an intermediate stage of maturation and increase again with terminal differentiation. A less common pattern of antigen expression, exemplified by CD64, is characterized by an absence of expression on myeloblasts, an increase at intermediate stages of maturation, and a loss with terminal differentiation [58, 59, 60, 61] .
Wood [61] with bright CD66b without CD16. Differentiation to the mature eosinophil is accompanied by an increased level of CD45, a mild decrease in SSC, and an increase in CD11b with a decrease in CD33.
Malignant stem and progenitor cells
High proliferative potential, capacity for self-renewal and developmental plasticity make HSCs and progenitor cells ideal target for malignant transformation. Several lines of experimental evidence suggest that leukemias might contain some leukemic stem cells (LSCs), which are rare cells with indefinite proliferation potential that drive the formation leukemic cells [62] . Transformation of normal hematopoietic cells have origin in genetic mutations and the signaling pathways that have been shown to be involved in the regulation of HSCs self-renewal, are also hypothesized to be associated with oncogenesis [63, 64, 62, 65] . It is not currently known for certain whether the mutations occur in the normal stem cells or in more differentiated cell types, which then acquire stem cell-like features [66, 67, 68] . Blair et al. [69] and Bonnet and Dick [70] published studies with a clear demonstration that most of the leukemic cells are unable to proliferate extensively and only a small, defined subset of cells -leukemic stem cells were consistently clonogenic. Bonnet and Dick [70] showed that the immature LSCs reside within only a small fraction of the CD34 + CD38
-subpopulation and are able to transmit acute myeloid leukemia (AML) to NOD-SCID mice and repopulate the bone marrow of the irradiated recipients. In contrast, CD34 + CD38 + AML cells are not able to engraft and repopulate NOD-SCID mice.
Acute myeloid leukemia (AML) is characterized by the uncontrolled overproduction of progenitor cells arrested in maturation and differentiation, and hierarchically organized similar to normal hematopoietic cells. On the top of this hierarchy are LSCs acting as AML-initiating and maintaining cells, whereas their more mature progeny AML blast cells are unable to maintain the long-term growth of leukemias [27, 71, 72] . Although LSCs have the potential for self-renewal, they spend the majority of time in the G 0 phase of the cell cycle. Chemotherapeutic drugs, which act on cell-cycle active cell populations, are less effective on LSCs than on leukemic blasts [73] . Chemotherapy-resistant leukemogenic LSCs, even if present in low numbers (minimal residual disease, MRD), may be responsible for the relapses in AML and are therefore considered to contribute essentially to the pathology and clinical outcome in these patients [27] .
Phenotype of leukemic stem cells. First immunophenotypic studies of LSCs showed phenotype pattern similar to HSCs -CD34
- [70, 71] . Recent phenotypic studies revealed the expression of additional LSCs surface antigens and despite functional and phenotypic similarities to HSCs, novel LSCsspecific antigens were found.
Taussig et al. [32] showed that myeloid markers CD13, CD33 are expressed not only on HSCs but also on LSCs and 
CD38
-LSCs were found to vary among donors. Heterogeneous expression, often in dependence on donors, was observed also for markers CD116 (GM-CSFRα), CD117 (SCFR), CD71, CD133 (AC133), HLA-DR [74, 75] . In contrast to previous studies, Blair et al. [76, 77] and van Gosliga et al. [78] showed no expression of CD71, HLA-DR, and CD117 on LSCs.
Numerous investigations have provided evidence that LSCs express considerable amounts of the CD123 (IL-3 receptor α chain) [32, 72, 74, 79, 80] , compared to lower level of CD123 expression on HSCs in normal and regenerating bone marrow [75, 81] . Florian et al. [75] observed increased expression of CD44 on LSCs. van Rhenen et al. [31, 32] 
CD96
+ AML cells also showed ability to engraft bone marrow of the recipient mice.
Phenotype of AML blast cells. The progeny of LSCs -AML blasts are due to their arrest in maturation and differentiation phenotypically partially similar to normal granulocyte progenitors, but they often possess imunophenotype abnormalities not typical for normal myeloid development. Multiple studies have been done to assess phenotypic abnormalities in AML blasts (leukemia-associated immunophenotypes, LAPs) which are totally absent or present at very low levels in normal bone marrow and bone marrow recovering from induction or consolidation chemotherapy [84, 85] . LAPs include expression of markers not normally expressed on myeloid cells, asynchronous coexpression of markers normally expressed at different stages of maturation as well as overexpression or underexpression of myeloid markers [86] . These unusual phenotypes are detected on leukemic cells at diagnosis and can be used to monitor MRD after induction or consolidation therapy [85] .
There are several classification systems of AML. FrenchAmerican-British (FAB) classification from 1976 is based on the type, morphology and degree of maturity of the cells from which is leukemia comprised. FAB divides AML into 8 subtypes (M0 -M7) [87] . Immunophenotype of AML-M0, AML-M1, AML-M2, AML-M3 and AML-M4 blast subtypes is similar to granulocyte progenitors, whereas immunophenotype of AML-M5, AML-M6 and AML-M7 subtypes is more similar to monocyte, erythrocyte or megakaryocyte progenitors. However, FAB classification doesn't reflect biologic features, genetic characteristics and prognostic factors of leukemic blasts. The World Health Organization (WHO) classification from 2001 reflects present knowledge on morphology, immunophenotyping, cytogenetics, molecular genetics, prognoses and responses to therapy [88] . Although the WHO classification is more specific, the FAB classification is still in use.
The most AML blast cells reside within CD34 + CD38 + cell fraction [70] . Early myeloblasts of undifferentiated AML (AML-M0), AML with minimal maturation (AML-M1), AML with maturation (AML-M2) and acute myelomonocytic leukemia (AML-M4) express CD34 and HLA-DR but these are lost by the pathologic promyelocytes which are typical for acute promyelocytic leukemia (APL or AML-M3) [89] . Similar to normal myelo-monoblasts, leukemic blasts have intermediate FSC, low SSC and low or intermediate CD45 [90] .
The leukemic cells in all cases of AML-M1 to AML-M4 commonly express various combinations of CD13, CD33, CD65, CD117 and myeloperoxidase (MPO), whereas blasts of AML-M0 express only CD34 and TdT without expression of CD13,CD33, CD117, MPO [91] . Expression of monocyteassociated markers CD4, CD14, CD64 is related to monocyte progenitors of acute myelomonocytic leukemia (AML-M4). Other myeloid associated markers CD11b, CD11c, CD13, CD33, CD15, CD65, CD66, and CD117 are also frequently expressed in various combinations on leukemic blasts but are not useful for distinguishing the different subtypes of AML [89] . The AML-M1 subtype is usually associated with asynchronous coexpression of T-cell markers -CD7 and CD4 [92, 93] . Zeleznikova et al. [90] showed the most frequent coexpression of CD7 mainly in subtypes M0-M2. Leukemic blasts in case of AML-M2 weakly express CD19, CD2 and less commonly CD56. Asynchronous coexpression of CD2 and CD56 is also associated with AML-M3 [94, 95] .
In future, synthesis of immunophenotype, cytogenetics and molecular genetics knowledge may elucidate of LAPs genesis and clarify the effect of LAPs and specific genetics changes in view of AML treatment and prognostic outcomes and may be important in design a more aggressive therapeutic approach.
In conclusion
Acute myeloid leukemia comprises heterogeneous group of malignant hematopoietic diseases that is characterized by proliferation and accumulation of immature myelopoietic progenitor cells in bone marrow. AML originates in transformation of hematopoietic stem cells or their progeny cells. Multiparameter flow cytometry method (FCM) analysis of human bone marrow became a major tool for a rapid and consistent diagnosis of AML. FCM provides exact determination of lineage specificity, stage of differentiation, aberrant intensity of leukemic cell gene expression and aberrant expression of lineage-specific or differential antigens. Detected leukemia associated phenotype is then used not only to ascertain exact diagnosis but is also used for determination of minimal residual disease during therapy and for post-therapeutic monitoring.
In some cases malignant transformation of leukemic cells doesn't result into formation of leukemia associated phenotype and leukemic cells possess identical phenotype like granulocyte progenitor cells. Absence of leukemia specific markers on leukemic cells and their small numbers make the follow up of minimal residual disease more difficult. Therefore it is still important to improve knowledge about normal bone marrow stem and progenitor cells phenotypes, identify new leukemiaspecific markers (CD96, CLL-1), search for aberrant marker expression and evaluate aberrant intensity or combination of various marker expressions for distinguishing normal cells from their malignant counterpart, in view of the diagnosis of leukemias or follow-up of minimal residual disease (MRD). Novel leukemia-specific markers also represent potential targets for example as a therapeutic agents based on monoclonal antibodies conjugated with cytostatic drugs.
